ZA93779B - Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. - Google Patents

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Info

Publication number
ZA93779B
ZA93779B ZA93779A ZA93779A ZA93779B ZA 93779 B ZA93779 B ZA 93779B ZA 93779 A ZA93779 A ZA 93779A ZA 93779 A ZA93779 A ZA 93779A ZA 93779 B ZA93779 B ZA 93779B
Authority
ZA
South Africa
Prior art keywords
cloning
expression
design
monoclonal antibodies
antibodies against
Prior art date
Application number
ZA93779A
Other languages
English (en)
Inventor
Chuan-Chu Chou
John S Abrams
Mary E Petro
Stephen Tindall
Paul J Zavodny
Nicholas J Murgolo
Chung-Her Jenh
Jon E Silver
William T Windsor
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA93779B publication Critical patent/ZA93779B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA93779A 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. ZA93779B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (1)

Publication Number Publication Date
ZA93779B true ZA93779B (en) 1993-08-05

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA93779A ZA93779B (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.

Country Status (21)

Country Link
US (1) US6451982B1 (xx)
EP (1) EP0625201A1 (xx)
JP (2) JPH07505767A (xx)
KR (2) KR0150060B1 (xx)
CN (1) CN1077991A (xx)
AR (1) AR248044A1 (xx)
AU (1) AU683836B2 (xx)
CA (1) CA2129445A1 (xx)
CZ (1) CZ291039B6 (xx)
FI (1) FI943635A0 (xx)
HU (1) HUT67943A (xx)
IL (1) IL104620A (xx)
NO (1) NO942912L (xx)
NZ (1) NZ249633A (xx)
PL (1) PL176393B1 (xx)
RU (1) RU94045919A (xx)
SG (1) SG49597A1 (xx)
SK (1) SK280610B6 (xx)
TN (1) TNSN93012A1 (xx)
WO (1) WO1993016184A1 (xx)
ZA (1) ZA93779B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0150060B1 (ko) 1992-02-06 1998-08-17 에릭 에스. 딕커 사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
SI1527100T1 (sl) 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
WO2004036190A2 (en) * 2002-10-16 2004-04-29 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP1810690B1 (en) 2004-10-28 2012-01-18 Kyowa Hakko Kirin Co., Ltd. Anti-IL-5 receptor antibody for use in treating endometriosis.
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2008134724A2 (en) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
CA2738001A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
EA034864B1 (ru) 2014-09-08 2020-03-31 Сефалон, Инк. Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
WO2017033121A1 (en) 2015-08-24 2017-03-02 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
BR112020005766A2 (pt) * 2017-09-29 2020-10-13 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ATE98872T1 (de) * 1988-11-03 1994-01-15 Schering Corp Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
KR0150060B1 (ko) 1992-02-06 1998-08-17 에릭 에스. 딕커 사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현

Also Published As

Publication number Publication date
RU94045919A (ru) 1996-11-10
KR0150060B1 (ko) 1998-08-17
WO1993016184A1 (en) 1993-08-19
FI943635A (fi) 1994-08-05
IL104620A0 (en) 1993-06-10
IL104620A (en) 2000-02-29
HUT67943A (en) 1995-05-29
SK91894A3 (en) 1995-02-08
SK280610B6 (sk) 2000-05-16
PL176393B1 (pl) 1999-05-31
HU9402293D0 (en) 1994-10-28
EP0625201A1 (en) 1994-11-23
CZ191094A3 (en) 1994-12-15
JP2000210097A (ja) 2000-08-02
TNSN93012A1 (fr) 1994-03-17
SG49597A1 (en) 1998-06-15
AU683836B2 (en) 1997-11-27
FI943635A0 (fi) 1994-08-05
CZ291039B6 (cs) 2002-12-11
NO942912D0 (xx) 1994-08-05
AR248044A1 (es) 1995-05-31
CA2129445A1 (en) 1993-08-07
NZ249633A (en) 1995-12-21
NO942912L (no) 1994-10-06
JPH07505767A (ja) 1995-06-29
KR950700413A (ko) 1995-01-16
US6451982B1 (en) 2002-09-17
AU3656093A (en) 1993-09-03
CN1077991A (zh) 1993-11-03

Similar Documents

Publication Publication Date Title
ZA93779B (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
IL111926A0 (en) Humanized antibodies and uses thereof
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
EP0528951A4 (en) Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof
EP0676966A4 (en) Antibodies directed against binding associated epitopes.
EP0578515A3 (en) Humanized monoclonal antibodies.
GB8910395D0 (en) Human monoclonal antibody and hybridoma producing the same
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
PL320610A1 (en) Fragments of monoclonal antibodies of immunosuppressive activity
EP0498767A3 (en) Chimeric antiidiotypic monoclonal antibodies
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
PL323195A1 (en) Alpha unit of human integrin beta 2
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
ZA928880B (en) Tumor associated monoclonal antibody 88BV59.
AU5852094A (en) Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
EP0668923A4 (en) MONOCLONAL ANTIBODY.
GB9118013D0 (en) Monoclonal antibodies and their use
GB9210944D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use
GB9210929D0 (en) Monoclonal antibodies and their use